Merck & Co., Inc. is building out its autoimmune disease capability with the $1.85bn acquisition of Pandion Therapeutics, Inc. announced on 25 February. The bulk of Merck & Co.'s recent string of deals has been in oncology, but this acquisition appears to balance the scale in a different therapeutic area.
A newly public company focused on the development of precision immune modulators targeting key immune control nodes, Pandion has a discovery platform, several preclinical drug candidates and one clinical drug candidate in development for autoimmune diseases
